GlassScriptPhysician profile
David Fink
NPI 1255338844
$2,317.59
in general payments reported to CMS, 2019-2025
25 companies · $162 in 2025
The $162 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $325 · 2020: $373 · 2021: $508 · 2022: $378 · 2023: $304 · 2024: $268 · 2025: $162.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $680 · Education: $53.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $680.07 |
| Education | $53.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $478.31 | 2019-2025 | |
| Amgen INC. | $198.78 | 2019-2023 | Prolia, Evenity |
| Astellas Pharma US INC | $181.29 | 2022-2025 | Veozah |
| Evofem Biosciences, INC. | $178.15 | 2021-2025 | Solosec, Phexx, Phexxi |
| Therapeuticsmd, INC. | $157.96 | 2019-2021 | |
| Mylan Pharmaceuticals INC. | $128.18 | 2019-2022 | |
| Sumitomo Pharma America, INC. | $109.71 | 2023-2024 | Myfembree |
| Myovant Sciences INC. | $108.31 | 2021-2022 | |
| Sage Therapeutics, LLC | $89.24 | 2022-2025 | Zurzuvae |
| Amag Pharmaceuticals, INC. | $85.00 | 2019-2021 | |
| Mission Pharmacal Company | $82.62 | 2019-2020 | |
| Exact Sciences Corporation | $67.82 | 2024-2025 | Cologuard Collection Kit |
| Exeltis, USA INC. | $57.22 | 2024-2025 | Slynd |
| Millicent US INC | $53.40 | 2024 | |
| Agile Therapeutics, INC. | $52.86 | 2022-2024 | Twirla |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avion Pharmaceuticals | $50.68 | 2021-2023 | Balcoltra |
| Daiichi Sankyo INC. | $48.87 | 2019-2021 | |
| Covidien LP | $39.17 | 2019 | |
| Radius Health, INC. | $33.16 | 2023 | |
| Allergan, INC. | $27.02 | 2019-2020 | |
| Shield Therapeutics INC | $24.23 | 2025 | |
| Lupin INC. | $24.22 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.96 | 2019 | |
| Dynavax Technologies Corporation | $12.74 | 2023 | Heplisav-B |
| Coopersurgical, INC. | $11.69 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Fink listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.